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a b s t r a c t
Adequate medical care of the increasingly ageing population requires robust clinical trial data both to
inform treatment decisions, and to understand the natural history of diseases which primarily affect
the elderly. However, this information is widely lacking, which is likely to have signiﬁcant clinical conse-
quences. Under-representation of older people in clinical trials iswell documented, the reasons including






designs remain conservative and there is no established standardised methodology for recruiting more
elderly patients with co-morbidities and disability into clinical trials. Designing clinical trials in older
people poses a unique set of challenges, particularly regarding recruitment, retention and data analysis.
In this review we outline the difﬁculties encountered in conducting clinical trials in older patients and
describe some of the initiatives that can be put in place to counteract them. It is only by addressing these
challenges with careful and adequately resourced protocol design that clinical trials may successfully
address the therapeutic questions raised by our ageing population.
© 2011 Elsevier Ireland Ltd. All rights reserved.
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. Introduction
The percentage of the UK population aged 65 years and over
elderly such as dementia: theworldwide prevalence of Alzheimer’s
disease is forecast to quadruple by2050, affecting1 in85people [2].
However, despite the need for trial data in the elderly population, its projected to increase from 16% in 2009 to 23% in 2034 [1]. The
argest increase is projected to be the very elderly (those aged 85
ears and over), rising from 1.4 million in 2009 to 3.5 million in
034 (5% of the total population) [1]. This increase in age will be
aralleled by increases in the prevalence of conditions affecting the
∗ Corresponding author. Tel.: +44 1752 437420; fax: +44 1752 517846.
E-mail address: camille.carroll@pms.ac.uk (C.B. Carroll).
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oi:10.1016/j.maturitas.2011.02.002iswidely lacking and it is likely that clinical treatment of the elderly
is being limited, as the extrapolation of trial data from a younger
population may not necessarily be valid [3]. Under-representation
of older people in clinical trials is well documented [4,5], the rea-
sons including physicians’ perception, protocol eligibility criteria,
and functional status requirements [6]. Inherent difﬁculties include
frailty, such that participation would be too onerous, and cognitive
decline leading to problems with consent and retention [21]. In
addition various factors result in failure to meet inclusion criteria,
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Table 1
Factors that contribute to effective research in the older person.
Successful strategies Limiting factors
General
Maximise patient involvement in all aspects of study design and implementation Restrictive inclusion and exclusion criteria
Minimise exclusion criteria
Anticipate nonresponse and attrition and consider measures to counteract, such as
oversampling or triggered sampling
Careful selection of non-onerous validated outcome measures
Plan for change over time such as development of cognitive impairment
Have ﬂexible dosing regimes in drug therapy trials, and plans to limit exclusion
Recruitment
Plan and resource several recruitment strategies Clinician gate-keeping
Consider pilot phase for recruitment strategy assessment Time commitment required from recruiter
Ongoing monitoring and adaptation of recruitment strategy Potential burden of study
Pay particular attention to needs of special groups e.g. ethnic minorities Impaired literacy in the elderly
Development of personal relationship between recruiter and participant Audio-visual impairment
Employ simple measures such as telephone follow-up of invitation letter Participant mistrust of researchers
Provision of information about studies to potential physician recruiters Lack of research awareness amongst health care professionals
Provision of research support and resource to physicians Practitioner time in clinic
Encourage endorsement of study by local health care practitioners
Retention
Develop strategy to cater for the speciﬁc needs of those at higher risk of attrition Mobility limitations
Ensure trial experience is positive Poor health of participants
Consider alternatives to study visits, such as home visits or telephone contact Hospitalisations
Develop ﬂexible study schedule
Consider use of a proxy to provide follow-up data
Consistent researcher throughout study
Analysis
Consider pilot phase to estimate missing data rates and potential protocol modiﬁcations Death or withdrawal
Develop strategy to minimise missing data within study design Incomplete completion of questionnaires or assessments
Incorporate adequate statistical methodology for missing data






























Consider use of multidimensional assessment of function rather than chronolo
uch as functional decline, polypharmacy, organ failure and insti-
utionalisation. Other barriers include the extra time and resources
eeded to recruit older patients, and the extra support they may
equire to ensure retention. Even when older people are included
n studies, selection bias occurs such that those who are healthier
nd with higher economic status tend to participate, casting doubt
n the general applicability of the results [7].
These problems affect all branches of elderly medicine – from
alls prevention to oncology. In some areas, such as oncology, there
avebeennational initiatives toboost geriatric involvement in clin-
cal trials and examine reasons why this is lacking, such as the
eriatric Oncology Consortium in the US. However, many clinical
rial designs remain conservative and there is no established stan-
ardised methodology for recruiting more elderly patients with
o-morbidities and disability into clinical trials.
Conducting a clinical trial involves several processes including
rotocol design, recruitment strategy, protocol implementation,
etention, analysis and dissemination of results. In this review we
utline the difﬁculties encountered in conducting clinical trials in
lder patients and describe some of the initiatives that can be put
n place to counteract them (summarised in Table 1).
. Protocol design considerations
In general, patient involvement should be sought for all stages
f clinical trial design to inform protocol development and ensure
ts acceptability to the target population. To maximise inclusive-
ess, exclusion criteria should be kept to a minimum. Investigators
hould consider whether measures need to be put in place to
ounteract the difﬁculties associated with nonresponse or nonpar-
icipation of patients who fulﬁl eligibility criteria, such as adopting
lternative randomisationmethods (e.g. cluster randomisation) [7].
hen selecting outcomemeasures, it is important to ensure that asge Study population may be ﬁtter with less co-morbity than the
general population
far as achievable, scales and assessment tools have been validated
for use in the target population, for example self-completion scales
developed in a younger population may have a form of wording
withwhich amore elderly participantmay not identify [8]. It is also
important to ensure that the outcome measure selected is appro-
priate for the stage of the disease it is being used to evaluate. For
example, the Alzheimer’s disease assessment scale – cognitive sub-
scale (ADAS-cog) was developed for the assessment of Alzheimer’s
dementia, and is now increasingly used in earlier stages of the
illness as early clinical diagnosis and interventions are being evalu-
ated. However, it has been demonstrated the sensitivity of the scale
is signiﬁcantly compromised at earlier disease stages, with pro-
nounced ceiling effects in several components [9], thereby limiting
its appropriateness for use in these sorts of studies.
Longitudinal studies have their own considerations [10] such as
the development of cognitive impairment during the course of the
study for which a plan must be in place in order to secure ongoing
informed consent. In addition there may be changes in the study
protocol, equipmentor softwareusedduring thecourseof the study
that need to be taken into account. Missing data are inevitable in
longitudinal studies involving the elderly and there needs to be
a clear plan in place to manage this, either by appropriate sta-
tistical methods or by planned missing designs [11]. In addition
the extent of missing data can be minimised by reducing time
required to complete the dataset by incorporating adaptive data
collection techniques such as item response theory (IRT) where
banks of items are ordered hierarchically in terms of difﬁculty,
or computer-adapted testing (CAT) where the testing session is
adapted to each participant [12]. These techniques also have the
advantage of reducing ﬂoor and ceiling effects of the outcomemea-
sures selected.
Trials of drug therapies are potentially more difﬁcult to perform
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cs, particularly with regard to reduced volume of distribution
nd reduced renal excretion [33], which may result in increased
rug toxicity andnecessitate dose adjustment. Other potential con-
ounders in the elderly are anaemia, altered hepatic metabolism,
nd drug–drug interactions from pre-existing medication regimes.
harmacodynamic considerations may also be relevant in the
lderly such as altered catabolism, enzymatic clearance or cel-
ular transport mechanisms. Nevertheless in order to determine
he beneﬁt/risk balance for any individual patient, it is impor-
ant that strategies are put in place to allow for recruitment
f these patients to clinical trials, such as GFR-dependent dose
djustment or treatment of anaemia with erythropoietin. Failure
o maximise inclusiveness in recruitment will result in failure
o recognise all those who may beneﬁt most from the proposed
herapy.
. Recruitment
Difﬁcultieswith recruitment can generally be divided into those
hich affect clinical trials in general, such as issues with clin-
cian gate-keeping, potential burden and time-commitment and
hose which are speciﬁc to a more elderly population, such as
mpaired literacy and audio-visual impairment. Several studies
ave investigated recruitment strategies in the elderly and some
ommon principles emerge [13–18], particularly the need to plan
nd resource several recruitment initiatives, have an adaptive ﬂex-
ble recruitment strategy, be aware of individual needs or those
f particular groups such as ethnic minorities [19], and develop
personal relationship between researcher and patient to max-
mise trust. The establishment of trust between participant and
esearcher is particularly important in qualitative research where
lder patients may be reluctant to discuss their experiences with
ounger researchersormay feel agreater senseof stigmaassociated
ith the condition being investigated [8].
Few studies have been designed speciﬁcally to investigate and
ompare recruitment strategies for older adults. However, a sys-
ematic review [20] has highlighted simple measures that can
e implemented such as follow-up of an invitation letter with a
elephone call, including trial documentation with the post-card
eminder and including a pencil with questionnaires for comple-
ion.
Recruitment strategies should be targeted speciﬁcally and can
ange fromadvertisements in themedia to face-to-face recruitment
y the patient’s own physician. In general face-to-face strategies
re more effective and can help overcome patient concerns and
ain acceptance and trust [15]. This is of particular relevance when
ecruiting to registers where it has been shown that age is a predic-
or of recruitment to a research registry [21], with a signiﬁcantly
ower level of recruitment in those aged over 60, reducing fur-
her with each decade. In addition, conducting community-based
r epidemiological research may also require face-to-face recruit-
ent as telephone recruitment or posted material is less likely to
e effective in a population with a higher incidence of visual and
uditory impairment. Recruitment to this type of study can also be
oosted by forging linkswith charitable organisations representing
he elderly, or relevant community leaders or organisations.
Althoughphysician-based face-to-face recruitmentcanbeasuc-
essful strategy, it does depend on the physician being aware of
otential trials, being willing to recruit patients to studies and hav-
ng the time todo so.Within the context of abusy service, thesemay
emain aspirations. However, within the UK there are strategies in
lace to help overcome some encountered difﬁculties. Inclusion
f patients within the NHS in research and the importance of the
ractice of research as a core NHS activity are receiving increasing
ecognition [22]. Infrastructure now exists to assist with deliver-itas 68 (2011) 337–341 339
ing research opportunities to all patients within the NHS, delivered
via the research networks. Nevertheless, the process still requires
clinicians being aware of and willing to participate in the research
process. In specialties with well-established academic links, such
as neurology, or those who have a strong culture of research, such
as oncology, this poses less of a problem, but in other speciali-
ties the lack of research-interested or research-aware clinicians is
a limitation. The decreasing number of academic departments of
geriatric medicine may be a factor in reduced research awareness
in the UK [23] There is also the potential that the physician may
act as a ‘gate-keeper’ [24], thereby disenfranchising older patients,
despite evidence that patients themselves arewilling to participate
in clinical studies [6]. In one survey of physicians the main reasons
endorsed for not recruiting potentially eligible older patients to
trials were found to be transportation needs, comorbid conditions
not excluded by the eligibility criteria, but which the physician
believed would adversely affect the patient, toxicity of the treat-
ment, and patient ability to understand the trial [25]. Although
changing physicians’ perceptions to inclusion of older patients in
trialsmaynot be straightforward [26], it is important that this is not
neglected, as endorsementof a studyby thepatient’s ownphysician
can be a powerful recruitment tool [27].
Ongoing monitoring of the success of the initial recruitment
method and adaptability to deal with encountered difﬁculties
should form part of the study design. This may well lead to
an increased resource requirement for the recruitment phase of
the study [14], with one published estimate of recruitment cost
being $255.40 per completing participant [19]. It may therefore
be worthwhile considering a pilot phase to investigate alternative
recruitment strategies.
4. Retention
Dropout during a trial can adversely affect the outcome of the
study: the reduction in numbers may reduce the power, or the
remaining sample may introduce bias. When designing a study
measures should therefore be put in place both to maximise reten-
tion and to prevent bias.
It has been demonstrated that participants who are younger,
perform better cognitively and are more highly educated have
higher retention rates [21]. It is therefore important to identify
those individualswhohave ahigher risk of attrition,which includes
the elderly, and ensure strategies are in place to cater for their
speciﬁc needs. A simple principle is to ensure that the trial experi-
ence is positive and beneﬁcial, safe, in a readily accessible physical
environment. The beneﬁt of the trial may not necessarily be the
possibility of being allocated a potentially beneﬁcial therapy; it
might be personal education or a sense of helping others [28]. With
regard to retention, a qualitative study by Schlenk [28] identiﬁed
5 factors which contribute positively: the belief of an obligation to
completewhathasbeenstarted; reciprocity to themedical commu-
nity; test results being of value in ongoing medical management; a
health advantage even if by increased awareness or education; and
socialization. This last is not to be underestimated in a population
in which social isolation is common. A particular factor which can
adversely affect retention of older trial participants is mobility lim-
itation which can affect 26% of those aged between 65 and 74 years
of age [28]. Measures can be put in place during the design phase of
the protocol that will assist with retention of this group: avoid-
ance of prolonged and numerous site visits, study visits carried
out in locations with convenient parking and access, provision of
transportation where appropriate, telephone or home visits where
possible.
Factors that increase likelihood of attrition are taking part in
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ive impairment and length of follow-up [29]. Means to overcome
his may include oversampling of these groups in the initial phase
o ensure sufﬁcient numbers at follow-up, or to utilise triggered
ampling designs. In addition, protocols should have the facility for
exibility regarding study dates, so that they can be rearranged if
he participant is unwell; facilitate the presence of a family mem-
er to assist with interviews and study visits; obtain permission to
ontact aproxy tohelp locate thepatient at the timeof follow-up, or
o contribute follow-up data; use the same researcher throughout
he study if possible [30].
. Analysis
Analysis of studies involving elderly participants poses a unique
et of challenges due to the nature of the study population and
he types of study being performed. Indeed it has been proposed
hat a subdiscipline of ‘gerontologic biostatistics’ be developed
o facilitate development of analytical techniques and training of
uture researchers [31]. Challenges which require statistical atten-
ion include the use ofmultiple interventions and outcomes, health
tate transitions, ﬂoor and ceiling effects of outcome measures and
issing data.
The problem of missing data affects all studies but is likely to
e greater in trials which involve the elderly, due to factors such
s incomplete completion of questionnaires, physical and cogni-
ive problems limiting ability to complete assessments, and loss to
ollow-up limiting the internal and external validity of the results
32]. Strategies to minimise missing data should be developed and
ncorporated into all phases of study design andhave been compre-
ensively reviewedbyHardyetal. [32]. Ingeneral strategies include
eﬁning readily obtainable primary outcome measures, prioritiz-
ngdata collection, developing alternativedata collection strategies
nd ensuring adequate allocation of resources. Designing a study
o maximise data collection will involve balancing the competing
equirements of minimizing exclusions and maximising retention
nddata completion. In addition it is important to accurately collect
nd describe the reasons for missing data or protocol deviations,
nd the characteristics of these study sub-populations. This will
ssistwith interpreting the generalisability of the studyﬁndings. As
ith development of recruitment strategies, incorporating a pilot
hase can assist with providing estimates of missing data rates
nd identiﬁcation of study procedures or outcomes which may
equire modiﬁcation, as well as determining the reliability of any
roxy-completedmeasures.Missing data can be deﬁned asmissing
ompletely at random (MCAR), missing at random (MAR) or miss-
ng not at random (MNAR). Although most missing data fall into
he last category, most standard statistical and analytical compen-
atory techniques assume the data are MCAR or MAR. Appropriate
tatistical methods should therefore be incorporated into the anal-
sis plan to deal with missing data whilst minimising introduction
f bias [11].
. Interpretation of results
Solutions to the problem of making trial data derived from
ounger, ﬁtter elderly participants more generalisable to the less
ell population include the use of geriatric assessment question-
aires that describe the degree of co-morbidity and general health
n the study population. Geriatric assessments of domains such as
evels of cognitive dysfunction, and number and severity of co-
orbidities are known to be associated with patients’ tolerance of
ew treatments and long-term survival and as such are performed
xplicitly or implicitly when making therapeutic decisions. How-
ver, such assessments rarely form part of clinical trial protocols.itas 68 (2011) 337–341
In order to determine whether special measures are likely to be
required in recruitment, retention or trial protocol with particu-
lar patients it is useful to have a multidimensional measure rather
than chronological age. One such measure is the comprehensive
geriatric assessment (CGA) which assesses function, comorbidity,
socioeconomic conditions, cognition, emotional conditions, phar-
macy, nutrition and geriatric syndromes [33]. Using the CGA has
been reported to allow identiﬁcation of 3 groups of patients: those
who are functionally independent without serious comorbidity;
those requiring assistance with one or more ADLs or with one or
two comorbid conditions; and those who are frail. Adoption of an
assessment tool such as the CGA for all patients over the age of
70 years would serve the dual purposes of: (1) the identiﬁcation
of new problems speciﬁc to the individual which may limit their
trial participation; and (2) allowing assessment to be made of the
generalisability of trial results to other patient groups. Another pro-
posed measure is the geriatric minimum data set (GMDS-25) [5],
thepurposeofwhich is toprovide standardisationofnomenclature,
assessment tools and diagnostic criteria. Standardisation of report-
ingwouldhave the additional advantageof facilitating comparative
studies and meta-analyses.
Reporting of the characteristics of responding and non-
responding nonparticipants will also assist in assessing the
generalisability and interpretationof the study results, as those that
do not respond aremore likely to have signiﬁcant co-morbidities or
be hospitalised, and may be the group most likely to beneﬁt from
the investigated intervention. If there is signiﬁcant non-response it
may be that the results cannot be generalised even to others that
meet eligibility criteria [7].
7. Conclusions
Designing clinical trials in older people poses a unique set of
challenges, particularly regarding recruitment, retention and data
analysis. It is only by addressing these challenges with careful and
adequately resourced protocol design that clinical trials may suc-
cessfully address the therapeutic questions raised by our ageing
population.
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